Yayın:
Pharmacokinetics of tolfenamic acid in goats after different administration routes

dc.contributor.authorTurk, Erdinc
dc.contributor.authorTekeli, Ibrahim Ozan
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorCorum, Orhan
dc.contributor.authorAltinok Yipel, Fulya
dc.contributor.authorIlhan, Aysun
dc.contributor.authorEmiroglu, Sara Busra
dc.contributor.authorUguz, Halis
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-04T15:06:50Z
dc.date.issued2021-02-09
dc.description.abstractAbstractThe aim of this study was to determine the pharmacokinetics and bioavailability of tolfenamic acid in goats after intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations at 2 mg/kg dose. In this study, eight clinically healthy goats were used. The study comprised four periods, according to a crossover design with at least a 15‐day washout period between treatments. Plasma concentrations of tolfenamic acid were determined by HPLC‐UV, and the pharmacokinetic parameters were estimated using a non‐compartmental method. Following IV administration, terminal elimination half‐life, volume of distribution at steady state, and total clearance were 1.60 h, 0.37 L/kg, and 0.27 L/h/kg, respectively. The mean peak plasma concentration following IM, SC, and PO administrations was 1.77, 1.22, and 0.30 μg/ml, respectively. The mean bioavailability following IM, SC, and PO administrations was 64.46, 55.43, and 19.46%, respectively. The PO route, which exhibits both the low plasma concentration and bioavailability, is not recommended in goats. The IV, IM, and SC routes, which show comparable pharmacokinetic profiles, may be proposed for use in goats. However, the multi‐dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in the goat.
dc.description.urihttps://doi.org/10.1111/jvp.12949
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/33560540
dc.description.urihttps://dx.doi.org/10.1111/jvp.12949
dc.identifier.doi10.1111/jvp.12949
dc.identifier.eissn1365-2885
dc.identifier.endpage373
dc.identifier.issn0140-7783
dc.identifier.openairedoi_dedup___::c8321d67fdca7893d82b8b6fadebfe28
dc.identifier.orcid0000-0003-1735-1774
dc.identifier.orcid0000-0002-6845-2279
dc.identifier.orcid0000-0003-1567-991x
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0001-8577-2031
dc.identifier.orcid0000-0003-3491-5949
dc.identifier.orcid0000-0003-0855-4967
dc.identifier.orcid0000-0002-9236-0630
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.pubmed33560540
dc.identifier.scopus2-s2.0-85100908473
dc.identifier.startpage367
dc.identifier.urihttps://hdl.handle.net/20.500.12597/38604
dc.identifier.volume44
dc.identifier.wos000616341800001
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsCLOSED
dc.subjectArea Under Curve
dc.subjectGoats
dc.subjectAnimals
dc.subjectortho-Aminobenzoates
dc.subjectHalf-Life
dc.subject.sdg2. Zero hunger
dc.subject.sdg3. Good health
dc.titlePharmacokinetics of tolfenamic acid in goats after different administration routes
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Erdinc Turk","name":"Erdinc","surname":"Turk","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1735-1774"},"provenance":null}},{"fullName":"Ibrahim Ozan Tekeli","name":"Ibrahim Ozan","surname":"Tekeli","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0002-6845-2279"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":3,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Fulya Altinok Yipel","name":"Fulya","surname":"Altinok Yipel","rank":5,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0001-8577-2031"},"provenance":null}},{"fullName":"Aysun Ilhan","name":"Aysun","surname":"Ilhan","rank":6,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3491-5949"},"provenance":null}},{"fullName":"Sara Busra Emiroglu","name":"Sara Busra","surname":"Emiroglu","rank":7,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0003-0855-4967"},"provenance":null}},{"fullName":"Halis Uguz","name":"Halis","surname":"Uguz","rank":8,"pid":{"id":{"scheme":"orcid","value":"0000-0002-9236-0630"},"provenance":null}},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":9,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"SDG","value":"2. Zero hunger"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Goats"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"ortho-Aminobenzoates"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Pharmacokinetics of tolfenamic acid in goats after different administration routes","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The aim of this study was to determine the pharmacokinetics and bioavailability of tolfenamic acid in goats after intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations at 2 mg/kg dose. In this study, eight clinically healthy goats were used. The study comprised four periods, according to a crossover design with at least a 15‐day washout period between treatments. Plasma concentrations of tolfenamic acid were determined by HPLC‐UV, and the pharmacokinetic parameters were estimated using a non‐compartmental method. Following IV administration, terminal elimination half‐life, volume of distribution at steady state, and total clearance were 1.60 h, 0.37 L/kg, and 0.27 L/h/kg, respectively. The mean peak plasma concentration following IM, SC, and PO administrations was 1.77, 1.22, and 0.30 μg/ml, respectively. The mean bioavailability following IM, SC, and PO administrations was 64.46, 55.43, and 19.46%, respectively. The PO route, which exhibits both the low plasma concentration and bioavailability, is not recommended in goats. The IV, IM, and SC routes, which show comparable pharmacokinetic profiles, may be proposed for use in goats. However, the multi‐dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in the goat.</jats:p>"],"publicationDate":"2021-02-09","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_14cb","label":"CLOSED","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"373","iss":null,"sp":"367","vol":"44","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::c8321d67fdca7893d82b8b6fadebfe28","originalIds":["10.1111/jvp.12949","50|doiboost____|c8321d67fdca7893d82b8b6fadebfe28","33560540","3127183243"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12949"},{"scheme":"pmid","value":"33560540"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":14,"influence":3.1057539e-9,"popularity":1.2590866e-8,"impulse":13,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12949"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12949"],"publicationDate":"2021-02-09","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"33560540"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12949"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/33560540"],"publicationDate":"2021-11-24","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12949"},{"scheme":"mag_id","value":"3127183243"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12949"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar